Skip to main content
. Author manuscript; available in PMC: 2022 Nov 1.
Published in final edited form as: Eur J Nucl Med Mol Imaging. 2021 May 8;48(12):3940–3950. doi: 10.1007/s00259-021-05386-0

Fig. 2.

Fig. 2

Representative cases. (A) Patient diagnosed with secondary CNS lymphoma. Contrast-enhanced T1-weighted MRI shows three enhancing lesions (left, orange arrows), which demonstrate focal [18F]FDG uptake on axial fused PET/MRI (middle, white arrows) and PET images. (B) A representative case of primary CNS lymphoma with a single FDG-avid lesion. Contrast-enhanced T1-weighted MRI depicts an enhancing lesion (left, orange arrow); fused PET/MRI (middle, white arrow) and PET images confirmed focal [18F]FDG uptake. (C) In a patient with primary CNS lymphoma, contrast-enhanced T1-weighted MRI shows a small subependymal enhancement in the right occipital horn (left, orange arrow) that has no correlate on fused PET/MRI (middle, white arrow) or PET images.